for phase 1 drug, the MC of AGN is actually relatively high compared to some peers.
@Lefevre, have you seen an ASX biotech have any big pharma interest this early in the game? Genuine question, as non dilutive support from big pharma in P1 or pre P2 enrollment would be first for me for asx company. I’d love for it to happen, just not sure if there is past examples
for phase 1 drug, the MC of AGN is actually relatively high...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
0.020(2.70%) |
Mkt cap ! $97.35M | |||
| Open | High | Low | Value | Volume |
| 73.5¢ | 76.0¢ | 72.3¢ | $96.97K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 73.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.40pm 27/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |